GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GlaxoSmithKline Plc (NYSE: GSK) said its anemia drug for patients with chronic kidney disease succeeded in five late-stage trials. The drug, daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, works by copying the body's response to hypoxia (low oxygen levels) and boosts the production of red blood cells by mimicking the body's response to high altitude.

GlaxoSmithKline's Anemia Candidate Shows Promise In Late-Stage Studies

GlaxoSmithKline plc (NYSE: GSK) is planning to sell more than one-third of its 92-acre R&D site in Stevenage, the U.K.  The Company is looking to sell 33 acres of the site and unlock up to £400 million ($554 million) of investment from a private sector developer to build a campus for biotechs and other early-stage life science companies.

GSK To Sell One-Third Of Its UK R&D Site For £400M

GlaxoSmithKline PLC (LON:GSK) is looking for a buyer for 33 acres of land where it hopes to co-develop a large ‘cluster' or 'campus' for biotech and other early-stage life science companies. Selling the land, which is part of the FTSE 100 company's existing 92-acre research & development site in Stevenage, Hertfordshire, should “unlock” up to £400mln in new investment from a property developer to build the new campus, it said.

GSK plans to create giant UK biotech cluster

Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising 400 million pounds ($552.76 million) through the sale of some land at the facility.

GSK seeks to expand England R&D facility with new $550-million plan

The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare.

GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022

Curaleaf Holdings, Inc.

Danaher

IQVIA Hlds

Intuitive Surgical

Jazz Pharmaceuticals

LHC Group

Moderna

Invesco S&P 500 Equal Weight Health Care ETF

UnitedHealth Group

Vertex Pharmaceuticals

The 2020s could be the decade of healthcare stocks. Here are 10 companies and one ETF to watch not just for the remainder of this year, but well beyond.

11 Best Healthcare Stocks for the Rest of 2021

Sanofi

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate. The companies in May started global trials to include more than 35,000 adults to test the candidate and hope to get approvals by the end of 2021.

Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India

Elliott Management is mounting an activist campaign to oust management

Buy GlaxoSmithKline for its Consumer Health Spin-Off

Heavyweight Wall Street bank Morgan Stanley has provided little encouragement to GlaxoSmithKline PLC (LON:GSK) following a long-awaited strategy review designed to assuage unrest among investors unhappy with the drugs giant's mediocre performance. Key among the initiatives designed to address the criticisms from the side-lines, including those of activist shareholder Elliott Management, were the spin-off of the consumer healthcare division and the setting of some ambitious growth targets for the rump pharma and vaccines business.

GlaxoSmithKline: This is what one leading Wall Street bank thinks of the CEO's plans

Alector Inc

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.

Why Alector Blasted Higher Today

One of these companies is making big waves.

Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring

GlaxoSmithKline plc (NYSE: GSK) said its board sees Chief Executive Emma Walmsley as the right person to lead its pharmaceutical business after the upcoming split with its consumer-health unit. The board "fully supports" the steps she's taking to improve performance, GSK said in a statement Friday.

GlaxoSmithKline's Board Backs CEO Walmsley After Elliott's Letter For Management Shakeup

Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher appeared first on InvestorPlace.

ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher

Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranulin (PGRN) levels.  PGRN is a crucial regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders.

Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK

GlaxoSmithKline PLC (LON:GSK) said it might be open to a sale of its consumer health business but is fully supportive of chief executive Emma Walmsley. Responding to demands activist investor Elliott Management published yesterday in an open letter, the pharma giant said: “The board strongly believes Emma Walmsley is the right leader of New GSK and fully supports the actions being taken by her and the management team, all of whom are subject to rigorous assessments of performance.

GlaxoSmithKline backs under fire CEO and adds Parkinson's and Alzheimer's drugs to portfolio

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels. PGRN is a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, making it one of the most attractive genetically validated targets for the development of new immuno-neurology treatments.

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases

An activist investor seems to be pushing for one.

Is a Bigger Shake-Up at GlaxoSmithKline on the Way?

Pharma giant responds to attack from U.S. activist fund Elliott, backing CEO Emma Walmsley.

GlaxoSmithKline defends itself against activist Elliott, recognizing need for ‘improved and sustained value'

GSK on Friday backed Chief Executive Emma Walmsley to continue leading the pharmaceuticals group after it spins off its consumer healthcare arm, responding to activist investor Elliott's proposals for the British company.

Britain's GSK backs CEO after pressure from activist Elliott

Elliott Management has finally made its intentions around GlaxoSmithKline plc (NYSE: GSK) known and calls for changes to rescue GSK from what it called "years of under-management." In an open letter to GSK Chairman Jonathan Symonds, the investment firm wants a "fit-for-purpose" board to choose "the best possible leadership" for GSK and its upcoming consumer health spinoff.

Activist Fund Elliott Management Wants GlaxoSmithKline Board Shakeup For 'Years Of Under Management'

Cigna

The three stocks listed below could be of interest to growth-oriented investors, as they represent equities in businesses whose price-earnings ratios are below 20 while their trailing 12-month earnings per share increased significantly over the past year.

A Trio of Stock Picks for Growth-Oriented Investors

The shares of GlaxoSmithKline plc (NYSE:GSK) are up 0.4% at $39.96 this morning, following news that Elliott Management has urged the British pharmaceutical company to name a new set of board directors to decide the future of its CEO Emma Walmsley.

Activist Investor Calls for Leadership Shake-Up at GSK

Activist fund Elliott, which has taken a "significant" stake in pharmaceuticals group GSK, has written to the British company's board setting out five main recommendations to improve the company's performance.

News for GlaxoSmithKline Stock (GSK)